The right of first refusal provision would have eroded incentives for generic drug makers to seek out and set up deals for less developed countries. A generic company cannot invest time and millions of dollars if it has to hand negotiated contracts over to brand-name drug companies. Ultimately, giving legislated preference to the brand-name drug companies would have limited the competition that was intended for this initiative, and prevented generic participation.
Other amendments to Bill C-9 proposed by the generic pharmaceutical industry at the committee stage involved providing non-governmental organisations (NGOs) with the ability to purchase medicines for developing countries and changes to the compulsory licence requirements.
The government did pass amendments to the bill in late April, including amendments that eliminated the controversial 'right of first refusal' -a positive step. That provision was replaced, however, by another clause that could turn out to be nearly as harmful.
From the beginning of the process, the Canadian generics industry's overall approach to the legislation has been that the Canadian government should proceed with a straightforward and faithful implementation of the WTO decision. That agreement was achieved after years of divisive debate, during which the brand-name pharmaceutical industry and Western governments more than ably represented their interests. It is a poor precedent for Canada to unilaterally reopen an agreement so painstakingly negotiated in order to grant further rights to patent holders.
For example, one of the provisions included in the government's amendments will allow brand companies to take generic firms to federal court to litigate over a vaguely defined 'commercial in nature' provision. Another will allow brand companies to take generic firms to federal court to increase royalty payments.
It is unlikely that a Canadian generics company will spend the time and money fighting the brands in court over these contracts. Once the brand company initiates litigation, the generics firm will probably withdraw its request for a licence.
Draconian regulations of Canada's Patent Act specific only to the pharmaceutical industry already force generics companies to go through regular lengthy and costly litigation to offer their products on the Canadian market. In fact, Canadian generics manufacturers have been in court more than 325 times in the last decade with brand-name companies over these regulations. It would simply be unsustainable for generics companies to endure endless litigation to make drugs to export under the new legislation.
In the past, brand companies sued Nelson Mandela's government to stop generic drugs from being shipped to South Africa, and it is clear they will not hesitate to take Canadian generics companies to court. Brand companies will use the litigation, and the threat of litigation now entrenched in the legislation, to dissuade generics companies from pursuing contracts.
As noted above, the CGPA and a number of the NGOs had also asked that the Canadian government make amendments to allow NGOs, and not just governments, the right to purchase medicines under the new legislation. In an odd turn of events, the government first introduced this amendment, then, at the last minute, changed it to a requirement that the NGO must have the permission of the government of the country into which the drugs are to be exported. It is unclear why the government changed its mind, but the revised amendment was part of a package of amendments introduced on behalf of brand-name drug makers.
Another problem with the legislation is that it limits contracts to two years and only one renewal. This provision does not make sense for anyone, not the importing country or the generics manufacturer.
By definition, the legislation deals with medicines that are under patent in Canada. Many of the HIV/AIDS drugs are under patent for another ten years or more in Canada. Generics companies will be expected to research, develop and manufacture products for a limited export market. After a generic drug company has spent three to five years and millions of dollars developing a product it should be able to sell it for as long as the company can attract buyers with low prices.
The CGPA, NGOs and opposition Members of Parliament (MPs) were also unable to persuade the government to eliminate Schedule 1, which is the list of products to be covered by the legislation. International trade agreements do not require Canada to legislate or impose a list of drugs that can be produced for export. The WTO decision of 30th August defines 'pharmaceutical product' to include any patented product needed to address public health problems and specifically allows the importing country to determine what drugs are needed. Maintaining a list ultimately threatens the ease of access to medicines and undermines the proper authority of developing countries to determine their own health needs. It also allows the list of drugs to be manipulated through lobbying by brand-name companies.
For example, while the Bill C-9 was being debated, an opposition MP moved to add a number of drugs to Schedule 1. The MP was telephoned by a brand company representative who complained about the company's products being included in the MP's amendments. When the amendments were voted on, the government MPs did not support the addition of one of the company's products to the list. An antibiotic, clarithromycin, which is sold by Abbot Laboratories under the trade name BIAXIN Õ , was also to be added to Schedule 1 in an opposition amendment, but government MPs defeated the amendment when it was called for a vote. The defeat of this amendment was troubling as several Canadian generics firms have already begun developing clarithromycin and this product could conceivably be ready for export in short order.
The CGPA also encouraged the Canadian government to become directly involved in helping to make the initiative a reality. Unlike some of the large, multinational brand companies, most Canadian generics companies do not have staff on the ground in Africa and developing countries and do not have resources to provide support services.
It is hoped that the Canadian government will be an active participant in the process, working with generic companies, helping direct them to where the needs are, working with the international organisations and trying to get more competitively priced medicines onto the market and to the people who need them.
The CGPA and its member companies will be consulting with government officials over the summer months on the regulations. Once a final regime is in place, it may become clearer whether government has moved the global fight for affordable medicines forward.
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